ADVERTISEMENT



HEALTHCARE

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

July 20, 2019

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with"... Continue Reading

AHF to WHO: Ebola Response, Too Little, Too Late!

July 18, 2019

AHF to WHO: Ebola Response, Too Little, Too Late!

The World Health Organization (WHO) has finally declared a Public Health Emergency of International Concern (PHEIC) in the Democratic Republic of the Congo on July 17 as a long overdue acknowledgement that the current Ebola outbreak remains uncontained and still poses a significant threat to global health security. A PHEIC declaration carries legal obligations requiring affected states to cooperate with the WHO in coordinating an outbreak response plan and also puts the global public health community on notice signifying a substantial health security risk to the world. “The PHEIC declaration is a step in the right direction, but it should have been declared months ago,” said AHF President Michael Weinstein....... Continue Reading

Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics

July 18, 2019

Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics

Boehringer Ingelheim and Bridge Biotherapeutics Inc. today announced that they are entering into a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 for patients with fibrosing interstitial lung diseases, including IPF. BBT-877 is currently in Phase I clinical studies and is anticipated to enter Phase II testing within the next"... Continue Reading

AHF: Clock Is Ticking, WHO – Act Now on Ebola!

July 16, 2019

AHF: Clock Is Ticking, WHO – Act Now on Ebola!

With the first reported case of Ebola emerging this week in Goma, a populous city in the eastern Democratic Republic of the Congo (DRC) next to the Rwandan city of Gisenyi, medical care providers and public health advocates from AIDS Healthcare Foundation (AHF)"... Continue Reading

ResMed Inc. Completes $500M Private Placement Debt Offering

July 16, 2019

ResMed Inc. Completes $500M Private Placement Debt Offering

ResMed Inc. (NYSE: RMD, ASX: RMD) announced today the successful pricing and closing of a private placement offering of $250,000,000 principal amount 3.24% senior notes due July 10, 2026, and $250,000,000 principal amount 3.45% senior notes due July 10, 2029.

Net proceeds from the offering will be approximately $498 million, after"... Continue Reading

CosmeSurge, the pioneer in aesthetic services, launches its 15th clinic

July 16, 2019

CosmeSurge, the pioneer in aesthetic services, launches its 15th clinic

CosmeSurge, one of the region’s most trusted brands for cosmetic and aesthetic procedures, has launched its 15th centre in the UAE and Oman. Located on the second floor of Bareen International Hospital in Mohammed Bin Zayed City, Abu Dhabi, the centre will provide innovative, high quality aesthetic and cosmetic dermatology and plastic surgery services for which the brand is renowned.

NMC"... Continue Reading

SpeeDx Receives Clearance from Health Canada for ResistancePlus® MG Test

July 16, 2019

SpeeDx Receives Clearance from Health Canada for ResistancePlus® MG Test

SpeeDx Pty. Ltd. today announced ResistancePlus® MG has been cleared by Health Canada and is now available for sale across all Canadian provinces (not currently available in the U.S.). The molecular diagnostic test detects the sexually transmitted infection (STI) Mycoplasma genitalium, also known as Mgen, along with genetic markers linked to antibiotic resistance. This is the first commercially available"... Continue Reading

New Study Investigates the Utility of Masimo ORi™, Oxygen Reserve Index, As an Indicator to Avoid Hyperoxia During General Anesthesia

July 16, 2019

New Study Investigates the Utility of Masimo ORi™, Oxygen Reserve Index, As an Indicator to Avoid Hyperoxia During General Anesthesia

Masimo (NASDAQ: MASI) announced today that in a study recently published in the Journal of Clinical Monitoring and Computing, researchers investigated the ability of Masimo ORi™ (Oxygen Reserve Index) to serve as a noninvasive indicator of the arterial partial pressure of oxygen (PaO2) during general anesthesia, to help avoid hyperoxia.1 ORi is an index of oxygenation in the moderate hyperoxic region (PaO2 range of 100 to 200 mmHg). As an “index” with a scale between 0.0 and 1.0, ORi can be trended to notify clinicians of changes in a patient’s oxygen reserve. Dr. Keisuke Yoshida and colleagues at the Fukushima Medical University School of Medicine in Japan sought to evaluate whether ORi...... Continue Reading

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform

July 15, 2019

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform

Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this"... Continue Reading

Alsayer Holding organizes blood donation campaign

July 14, 2019

Alsayer Holding organizes blood donation campaign

In partnership with Kuwait Central Blood Bank (CBB), Al Sayer Holding Corporate Excellence Department organized blood donation campaigns as part of Corporate Sustainability and Community Services at Four Locations: ALSAYER Headquarter KFTZ1, Al-Rai Toyota Showroom, New Ardiya Delivery Center and Ahmadi Toyota Service Center.

More"... Continue Reading

Found articles: - Pages